Ocugen Inc Stock Price, News & Analysis

Ocugen (NASDAQ: OCGN) announced the issuance of U.S. Patent No. 11,351,225 on June 7, 2022, enhancing its gene therapy intellectual property portfolio. This patent covers methods for preventing and treating retinal degenerative diseases, including retinitis pigmentosa and age-related macular degeneration, using specific nuclear hormone receptor genes. The patent, set to expire in March 2034, validates Ocugen's modifier gene therapy platform and strengthens its global patent position.

MALVERN, Pa., June 9, 2022 – Ocugen (NASDAQ: OCGN) announced that Michael Shine, VP of Commercial, will present at the 2022 BIO International Convention in San Diego from June 13-16, 2022. The presentation is set for June 13 at 4:45 p.m. PT, focusing on Ocugen’s clinical pipeline, including its COVID-19 vaccine candidate, COVAXIN™, modifier gene therapy programs, and new cell therapy program, NeoCart®. Ocugen aims to develop innovative therapies to address unmet medical needs and improve global health.

Ocugen, Inc. (NASDAQ: OCGN) announced that its NeoCart^® therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, aiming to expedite development for knee cartilage repair in adults. This innovative cell therapy, a 3D-engineered cartilage product, could potentially prevent osteoarthritis by rebuilding damaged knee cartilage. Developed originally by Histogenics, NeoCart^® represents a significant step in Ocugen's regenerative medicine pipeline as they prepare for Phase 3 clinical trials.

Ocugen announced that Dr. Shankar Musunuri, the company's Chairman and CEO, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 1:30 PM ET in Miami Beach, Florida. The event focuses on the company's innovative gene therapies and vaccines aimed at improving health outcomes. Interested parties can register to watch the chat virtually. A replay will be available on the Investor’s section of the Ocugen website starting on May 24 for 90 days.

Ocugen, Inc. announces the lifting of the clinical hold by the U.S. FDA on its Phase 2/3 trial for COVAXIN™ (BBV152), a COVID-19 vaccine candidate. Dosing will resume immediately, affirming Ocugen's commitment to providing differentiated vaccine options. The vaccine has been administered over 350 million times globally, approved in India, and authorized in 25 countries. Further emergency use applications are pending in 60 others. Ocugen aims to advance this critical vaccine's development in the U.S., Canada, and Mexico amidst ongoing global demand.

Ocugen, Inc. (NASDAQ: OCGN) reported its first quarter 2022 results, indicating a cash position of $129.9 million, up from $95.1 million in Q4 2021. Significant milestones include the Phase 1/2 trial for OCU400, with the first patient dosed in March and a second in May. The company expanded its COVAXIN™ marketing rights to cover all of North America, including Mexico. R&D expenses rose to $7.9 million from $2.9 million year-over-year. The net loss was $0.09 per share, compared to $0.04 last year. A conference call is scheduled for further discussion.

Ocugen, Inc. (NASDAQ: OCGN) announced a conference call scheduled for May 6, 2022, at 8:30 a.m. ET, to discuss its first quarter 2022 financial results. The company will issue a pre-market earnings announcement on the same day. Investors can join the call via a toll-free dial-in number or through a webcast available on Ocugen's website for approximately 45 days post-call. Ocugen focuses on developing innovative gene therapies and vaccines aimed at addressing unmet medical needs.

Ocugen, Inc. (NASDAQ: OCGN) announced two significant presentations at the ARVO 2022 Annual Meeting related to its innovative treatments for age-related macular degeneration (AMD) and diabetic macular edema (DME). The company is showcasing its RORA modifier gene therapy, OCU410, aimed at treating dry AMD, and a biologic product candidate, OCU200, for wet AMD and DME. Both presentations highlight promising approaches to combat these vision-threatening conditions, which currently have limited treatment options and affect millions.

Ocugen announced that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of its Phase 1/2 clinical trial for OCU400, a modifier gene therapy candidate aimed at treating Retinitis Pigmentosa linked to NR2E3 and RHO mutations. The study recently dosed its first patient, and there were no serious adverse events reported. This therapy has the potential to address multiple retinal diseases with a single product, showcasing Ocugen's innovative approach in gene therapy.